Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study

In this post hoc LINKER-MM1 study analysis, linvoseltamab treatment in multiple myeloma patients initially showed high infection rates that declined markedly after six months. Respiratory and coronavirus infections were most common. Evolving infection protection protocols, including immunoglobulin replacement therapy, helped further mitigate severe infection risks over the extended treatment duration.